FibroScan / VCTE: Which Tests to Order Alongside It (Women's Guide)

What FibroScan / VCTE Actually Measures

FibroScan uses vibration-controlled transient elastography to send a shear wave through liver tissue and calculate how stiff the liver is, reported in kilopascals (kPa). A stiffer liver suggests more fibrosis. The probe also captures a controlled attenuation parameter (CAP) score, which estimates how much ultrasound signal is absorbed by fat, expressed in decibels per meter (dB/m).

The two numbers answer two different questions. Liver stiffness answers "how scarred is this liver?" CAP answers "how fatty is this liver?" You need both to stage metabolic dysfunction-associated steatotic liver disease (MASLD, the updated term for what was called NAFLD) properly.

Why "FibroScan" and "VCTE" Are Used Interchangeably

FibroScan is the brand name of the Echosens device. VCTE is the generic technology name. Clinical guidelines, including those from the American Association for the Study of Liver Diseases (AASLD), use VCTE as the preferred term in research, but your ordering clinician and your insurance form may say FibroScan. They refer to the same test.

What the Numbers Mean

| Liver Stiffness (kPa) | Fibrosis Stage Estimate | |---|---| | <7.0 | F0-F1 (none to mild) | | 7.0-9.6 | F1-F2 (mild to moderate) | | 9.7-13.5 | F2-F3 (moderate to advanced) | | >13.5 | F3-F4 (advanced to cirrhosis) |

| CAP Score (dB/m) | Steatosis Grade | |---|---| | <248 | S0 (minimal, <11% fat) | | 248-267 | S1 (mild, 11-33%) | | 268-279 | S2 (moderate, 34-66%) | | ≥280 | S3 (severe, >66%) |

Cut-offs vary slightly by probe type (M vs. XL). Published meta-analyses place the optimal VCTE cut-off for significant fibrosis (F2+) at approximately 8.2 kPa in MASLD cohorts, though individual labs often use slightly different thresholds.

Why Women Get a Different Risk Profile Than Men

Sex differences in liver disease are real, biologically grounded, and still under-studied. Women historically made up fewer than 35% of participants in the major MASLD natural-history trials, so some of what clinicians apply to women is extrapolated from predominantly male cohorts. This matters because estrogen, androgens, menstrual cycle phase, and reproductive history all change hepatic fat handling.

Estrogen's Protective Effect (and What Happens When It Leaves)

Estrogen suppresses hepatic de novo lipogenesis and promotes fatty acid oxidation. In premenopausal women, this creates a degree of metabolic protection relative to age-matched men. After menopause, that protection fades. A 2021 analysis in the journal Menopause found that postmenopausal women had significantly higher rates of MASLD compared with premenopausal women at the same body mass index, suggesting the liver-fat burden accelerates in the menopausal transition independent of weight gain alone.

This means a 54-year-old woman with a CAP score of 262 dB/m deserves a different clinical conversation than a 32-year-old with the same number.

PCOS and the Liver

PCOS is the most common endocrine condition in reproductive-age women, affecting roughly 8-13% of this group globally. Women with PCOS have a 2.5-fold higher odds of MASLD compared with BMI-matched controls without PCOS, driven largely by hyperinsulinemia and androgen excess rather than obesity alone. Lean women with PCOS can still accumulate significant hepatic fat. A lean woman with a BMI of 23 and a CAP score of 270 dB/m should have insulin resistance markers checked, not just reassurance that her weight is normal.

Thyroid Disease and Liver Fat

Hypothyroidism, which affects women at roughly 5-8 times the rate of men, independently raises hepatic triglyceride accumulation. A large Korean cohort study published in Clinical Gastroenterology and Hepatology found subclinical hypothyroidism associated with a 30% higher risk of MASLD, even after adjusting for BMI and metabolic syndrome components. TSH belongs on the paired-lab panel for women, period.

The Core Paired-Lab Panel for Women

Getting a FibroScan result without a metabolic and liver-chemistry panel is like getting an MRI without a clinical history. The number tells you something is happening; the labs tell you why and what to do next.

Liver Chemistry Panel

Order all four together:

• ALT (alanine aminotransferase): The most specific marker of hepatocellular injury. The American College of Gastroenterology (ACG) clinical guideline recommends using sex-specific ALT upper limits of normal: approximately 19-25 U/L for women versus 29-33 U/L for men. Many labs still use unisex ranges of 40-55 U/L, which means a woman with an ALT of 30 U/L may look "normal" by the lab printout but is actually mildly elevated by sex-specific standards. Ask your clinician which cutoff they are using.
• AST (aspartate aminotransferase): Rises in more advanced disease and in alcohol-related injury. The AST:ALT ratio helps distinguish cause.
• GGT (gamma-glutamyl transferase): Sensitive to alcohol, certain medications, and metabolic stress. Elevated GGT with an elevated CAP score is a particularly concerning combination.
• ALP (alkaline phosphatase): Elevated in cholestatic liver disease and in pregnancy (placental isoform). Interpret carefully if the patient is pregnant or in the third trimester.

Fibrosis Scoring: FIB-4 Index

The FIB-4 index (age × AST / platelet count × √ALT) is the lowest-cost fibrosis triage tool available. The AASLD and European Association for the Study of the Liver (EASL) jointly recommend FIB-4 as the first-line non-invasive test for MASLD-related fibrosis assessment, used before or alongside VCTE. A FIB-4 score below 1.30 has a high negative predictive value for advanced fibrosis (F3-F4). A score above 2.67 warrants further workup. FibroScan and FIB-4 together perform better than either alone.

Metabolic Panel

Order these as a set:

• Fasting glucose and fasting insulin (to calculate HOMA-IR; a HOMA-IR above 2.5 suggests insulin resistance)
• HbA1c (identifies prediabetes and diabetes, both of which accelerate MASLD progression)
• Fasting lipid panel (triglycerides and low HDL are the metabolic syndrome components most tightly linked to hepatic steatosis)
• Uric acid (elevated in insulin resistance and predicts MASLD severity independently)

Hormone Panel (Women-Specific)

This is where most general-medicine workups fall short for women:

• Fasting insulin and total/free testosterone: In reproductive-age women, androgen excess is the biological driver linking PCOS to hepatic fat. A woman with a CAP score above 268 dB/m and irregular cycles needs a full androgen panel, not just a metabolic panel.
• TSH (and free T4 if TSH is abnormal): As above, hypothyroidism is a modifiable cause of hepatic steatosis in women.
• Estradiol and FSH: In perimenopausal or postmenopausal women, knowing the hormonal milieu helps contextualize why liver fat is rising and opens a conversation about whether hormone therapy might be appropriate for other indications.
• SHBG: Low SHBG is a surrogate marker for insulin resistance and hyperandrogenism and predicts MASLD risk in women independently.

The WomanRx Paired-Lab Framework for FibroScan Results in Women organizes these into three tiers by life stage:

Reproductive-age women (18-44): ALT (sex-specific cutoff), AST, GGT, FIB-4 components (platelet count), fasting glucose + insulin, HbA1c, lipid panel, TSH, total testosterone, free testosterone, SHBG, LH/FSH if cycles are irregular.

Perimenopausal women (45-55): All of the above plus estradiol, FSH, and uric acid. Add a DEXA scan referral if liver stiffness is ≥9.7 kPa (higher fibrosis stage correlates with lower bone density in this group).

Postmenopausal women (55+): Full metabolic panel, fasting insulin, TSH, and an assessment of current hormone therapy status. If the woman is not on hormone therapy and has a rising CAP score with worsening metabolic markers, a discussion of menopausal hormone therapy for its metabolic and bone indications is appropriate, separate from the liver itself.

Understanding a High FibroScan Result

A liver stiffness measurement at or above 9.7 kPa places a patient in the range where MASLD-related fibrosis is clinically significant (F2-F3 or higher). This is the threshold used in the prescribing criteria for resmetirom (Rezdiffra), the first FDA-approved treatment for MASLD with moderate to advanced fibrosis, approved in March 2024. Resmetirom is a thyroid hormone receptor-beta agonist that selectively activates hepatic thyroid signaling to reduce fat and fibrosis.

What Elevates Liver Stiffness Falsely

Liver stiffness measurements can be transiently elevated by:

• Recent food intake (perform the test after a 2-4 hour fast)
• Acute liver inflammation (ALT flare from any cause stiffens the liver temporarily)
• Right heart failure (back-pressure raises hepatic venous congestion)
• Significant ascites

If your result is unexpectedly high and any of these conditions apply, repeat the scan under controlled conditions before acting on the number.

The Role of Liver Biopsy

A FibroScan in the intermediate zone (7.0-13.5 kPa) combined with discordant FIB-4 results may still require liver biopsy to confirm fibrosis stage, particularly before starting resmetirom or enrolling in a clinical trial. AASLD guidance notes that biopsy remains the reference standard when non-invasive tests are discordant or when a specific histological diagnosis would change management.

Understanding a Low FibroScan Result

A liver stiffness below 7.0 kPa with a CAP score below 248 dB/m is reassuring, but not a reason to stop investigating metabolic risk in a woman with symptoms. MASLD can be present even when liver stiffness is normal if the CAP score is elevated. The fat (CAP) and the scar (kPa) progress at different rates.

A "low" liver stiffness result does not mean:

• Metabolic syndrome is absent
• Insulin resistance is absent
• The liver is healthy long-term without intervention

It means fibrosis is currently not advanced. Address the underlying drivers (insulin resistance, dyslipidemia, androgen excess, hypothyroidism) before the scar develops.

How to Lower a High FibroScan / Improve MASLD

Lifestyle: The Only Intervention Proven to Reduce Both Fat and Fibrosis

A 2019 Cochrane review confirmed that 7-10% body weight loss produces histological improvement in MASLD, including fibrosis regression in some patients. For women with PCOS, the combination of weight loss and insulin sensitization (metformin or, increasingly, GLP-1 receptor agonists) produces additive benefit on hepatic steatosis beyond weight loss alone.

Exercise, particularly 150 minutes per week of moderate-intensity aerobic activity, reduces CAP scores even in the absence of significant weight change, likely by reducing hepatic de novo lipogenesis and improving peripheral insulin sensitivity.

GLP-1 Receptor Agonists

Semaglutide 2.4 mg weekly (Wegovy) and liraglutide have both shown meaningful reductions in hepatic fat and liver enzymes in women with obesity and MASLD. The STEP-1 trial showed 14.9% mean weight loss with semaglutide 2.4 mg at 68 weeks, and hepatic steatosis improvements tracked closely with weight loss. The dedicated NASH semaglutide trials are ongoing.

Resmetirom

For women with confirmed F2-F3 fibrosis on VCTE or biopsy, resmetirom 80 mg or 100 mg daily is now an option. In the MAESTRO-NASH phase 3 trial, resmetirom achieved NASH resolution without fibrosis worsening in 25.9% of patients on 80 mg and 29.9% on 100 mg versus 9.7% on placebo. Women-specific data from that trial have not been published in a sex-stratified sub-analysis, which is a notable evidence gap.

Hormonal Interventions in PCOS

Metformin reduces hepatic glucose output and modestly reduces hepatic steatosis in women with PCOS. Combined oral contraceptives reduce androgen excess but may slightly increase hepatic triglyceride synthesis via the hepatic first-pass effect of estrogen, which is a trade-off worth discussing. ASRM recommends individualized assessment of metabolic risk when selecting hormonal therapy for PCOS.

Normal FibroScan / VCTE Range: What "Normal" Means for You

The published population reference range for liver stiffness in adults without liver disease is below 7.0 kPa. The CAP threshold for minimal steatosis is below 248 dB/m. But several factors shift what "normal" means for an individual woman:

• BMI: Higher BMI requires the XL probe. Using the M probe in a woman with a BMI above 30 overestimates stiffness. Probe selection errors affect up to 25% of patients in real-world settings.
• Menstrual cycle phase: No large study has tracked how cycle phase changes VCTE results, but hepatic blood flow and circulating hormone levels change substantially across the cycle. This is a genuine evidence gap.
• Menopausal status: Reference ranges for liver stiffness were established in mixed-sex, mixed-age cohorts. Postmenopausal women may have a different physiological baseline. This has not been formally studied.

Pregnancy and Postpartum Considerations

FibroScan is not a routine test during pregnancy. The shear-wave technology itself has no known fetal risk from a radiation standpoint (there is no ionizing radiation), but the clinical utility is limited because:

• Intrahepatic cholestasis of pregnancy and acute fatty liver of pregnancy are separate diagnoses managed differently from MASLD.
• Liver stiffness increases physiologically in the third trimester due to increased hepatic blood flow and vascular changes, making fibrosis staging unreliable.
• ACOG Practice Bulletin No. 232 addresses intrahepatic cholestasis of pregnancy and does not recommend VCTE for its evaluation.

If you were diagnosed with MASLD or elevated liver enzymes before pregnancy, your clinician should delay repeat FibroScan until at least 12 weeks postpartum, after resolution of any pregnancy-related liver changes. Resmetirom is contraindicated in pregnancy based on animal reproductive toxicity data; the FDA label for resmetirom states that females of reproductive potential should use effective contraception during treatment. There are no human data on lactation transfer of resmetirom; until data exist, breastfeeding is not recommended during treatment.

GLP-1 receptor agonists used for MASLD-adjacent weight management (semaglutide, liraglutide) are also contraindicated in pregnancy. Women of reproductive age who are prescribed these agents should use reliable contraception and discontinue at least 2 months before a planned conception (semaglutide's long half-life requires this washout period).

Who This Is Right For and Who Should Wait

Women Who Should Proceed With FibroScan Now

• Any woman with PCOS and abnormal liver enzymes or metabolic syndrome features
• Postmenopausal women with type 2 diabetes or prediabetes and elevated ALT
• Women with obesity and an elevated FIB-4 score (>1.30) on routine bloodwork
• Any woman being considered for resmetirom who needs fibrosis stage confirmation
• Women with a strong family history of cirrhosis or hepatocellular carcinoma

Women Who Should Wait or Repeat Under Better Conditions

• Pregnant women (delay to postpartum)
• Women within 2 hours of a meal (retest fasting)
• Women with an acute hepatitis flare or recent AST/ALT spike above 5x upper limit of normal (treat the flare first, then retest)
• Women with decompensated heart failure (congestion confounds stiffness readings)

Talking to Your Clinician: What to Ask

You may not get a full paired-lab panel unless you ask for it. Bring this list to your appointment:

1. "What sex-specific ALT cutoff are you using for my result?"
2. "Can you calculate my FIB-4 score from the labs I already have?"
3. "Should I have a HOMA-IR calculated, and what does it mean if it is above 2.5?"
4. "Given my menopause status / PCOS diagnosis / thyroid history, which hormone labs would change your management?"
5. "If my liver stiffness is above 9.7 kPa, am I a candidate for resmetirom, and what contraception do I need to be on before starting?"